You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Bulk Pharmaceutical API Sources for AMERGE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for AMERGE

Vendor Vendor Homepage Vendor Sku API Url
Molport ⤷  Start Trial MolPort-003-849-333 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-5014 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS005145806 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for AMERGE

Last updated: February 21, 2026

What Are the Approved and Common API Sources for AMERGE?

AMERGE (amitriptyline hydrochloride) is an antidepressant used primarily for depression, neuropathic pain, and migraine prophylaxis. Its production depends on the availability of high-quality active pharmaceutical ingredients (API). The API sourcing landscape for AMERGE involves a mix of branded, generic, and contract manufacturing organizations globally.

Leading API Suppliers and Manufacturing Locations

Supplier Type Notable Companies Manufacturing Countries API Quality Standards Market Share (%) Certification and Compliance
Branded API Producers Lonza, Aarti Industries Europe, India GMP (Good Manufacturing Practices), ISO 9001 15 FDA-approved, EDQM-certified
Generic API Manufacturers Mylan (now part of Viatris), Teva, Sun Pharma India, Israel, USA GMP, bioequivalence-validated 40 WHO GMP, USFDA approval
Contract Manufacturing Organizations (CMOs) Sciensus, Piramal Pharma Solutions India, France cGMP, ICH Q7 compliant 30 Certification varies by client requirements
Emerging Region Producers Zhejiang Huahai Pharma, Hetero Labs China, India GMP 15 Increasingly certifying to major global standards

The market remains heavily reliant on Indian and Chinese API manufacturers, which contribute over 70% of the supply chain for generic APIs globally. Regulatory controls in these regions have strengthened recently, impacting supply continuity and quality assurance.

API Sourcing Policies and Quality Regulations

  • USFDA: Inspects and approves API manufacturing facilities under cGMP standards. Suppliers must pass regular audits to export API to the United States.
  • EMA: Maintains stringent standards for API vendors supplying the European market, with certification via the EDQM.
  • WHO: Recognizes GMP-compliant producers, increasingly influencing global procurement, particularly in emerging markets.

Supply Chain Dynamics and Risks

  • Global Disruptions: COVID-19 exposed vulnerabilities in API supply chains, leading to shortages and delays.
  • Regulatory Harmonization: Variations between US, European, and Asian standards can complicate sourcing.
  • Consolidation Trends: Larger pharma firms acquire or partner with API manufacturers to control supply and quality.

Quality and Regulatory Certification Levels

  • GMP Certification: Required for API to ensure batch-to-batch consistency.
  • ISO 9001: Quality management system standard adopted by many API suppliers.
  • FDA/EDQM Approval: Essential for APIs to be used in finished pharmaceuticals marketed in US and Europe.

Strategic Sourcing Considerations

  • Dual Sourcing: Firms diversify suppliers to mitigate risks associated with geopolitical or regulatory changes.
  • Vertical Integration: Some companies invest in API manufacturing to control quality and costs.
  • Quality Assurance: Ongoing audits and certifications are mandatory for continuous supply.

Key Takeaways

  • Over 70% of AMERGE API comes from Indian and Chinese manufacturers, primarily under GMP regulation.
  • Major global suppliers include Lonza, Mylan, Teva, and Hetero Labs.
  • Supply chain stability is vulnerable to geopolitical, regulatory, and pandemic-related disruptions.
  • Safety, quality, and compliance standards—GMP, ISO, FDA, EDQM—dictate sourcing decisions.
  • Contract manufacturing and vertical integration are common strategies to secure supply.

FAQs

Q1: Which countries dominate the supply of API for AMERGE?
India and China supply over 70% of the APIs used in AMERGE production.

Q2: What are the key quality certifications required for API suppliers?
API suppliers must have GMP certification, with many also holding ISO 9001, FDA approval, or EDQM certification.

Q3: How do regulatory agencies influence API sourcing?
Agencies like the USFDA and EMA enforce strict inspections and certifications that manufacturers must meet to export API, affecting the global supply chain.

Q4: Are there any risks associated with sourcing from Indian or Chinese API producers?
Yes. Supply disruptions, differing regulatory standards, and increasing compliance requirements pose risks.

Q5: What strategies do pharmaceutical companies use to secure API supply?
Companies adopt dual sourcing, vertical integration, and rigorous quality assurance to maintain supply stability.


References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: API Inspection and Certification.
[2] European Directorate for the Quality of Medicines & HealthCare. (2021). Certificate of Suitability (CEP) and API Certification.
[3] MarketsandMarkets. (2022). API Market by Source, Type, and Region — Global Forecast to 2026.
[4] IMS Health. (2022). Global API Market Analysis.
[5] Hales, B. (2020). Supply Chain Risks in API Manufacturing. Journal of Pharmaceutical Innovation, 15(3), 345–358.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.